Onc.AI Awarded Significant Grant for Cancer AI Development
In an exciting advancement for oncology, Onc.AI, a pioneer in digital health, announced a substantial $2 million grant awarded by the National Cancer Institute (NCI). This funding aims to propel the development of their innovative AI-driven clinical decision support system specifically tailored for non-small cell lung cancer (NSCLC). The focus of this grant is to further clinical validation and enhancement of Onc.AI’s groundbreaking imaging-AI software.
Transforming Clinical Decision-Making in NSCLC
This grant will facilitate a comprehensive multi-institutional, prospective clinical study to evaluate NSCLC patients. Onc.AI's AI-based clinical decision support system has shown considerable promise in assisting oncologists to determine a metastatic NSCLC patient’s chances of achieving progression-free survival. This initiative builds on the previous successes the company experienced, particularly the impressive outcomes presented at the 2024 American Society of Clinical Oncology (ASCO) meeting.
At this prestigious event, Onc.AI showcased their ability to provide adjunctive support through a single pre-treatment CT scan, demonstrating a leap forward in how medical professionals can utilize imaging data for better outcomes.
Innovative Technology in Oncology
Onc.AI employs cutting-edge deep learning techniques to analyze and quantify complex imaging features. This analysis reveals critical insights regarding a patient’s likelihood of responding to immune checkpoint inhibitor (ICI) therapy alone. By identifying these subtle radiographic markers, Onc.AI equips oncologists with enhanced information to inform personalized treatment strategies for their patients.
The support from the NCI through this SBIR grant signifies a strong belief in the potential of AI technology to transform clinical practice. Onc.AI is committed to validating its AI-based decision support system in practical clinical environments to expand its applicability and efficacy, ultimately leading to improved patient outcomes.
Expert Insights on the Partnership
“Onc.AI’s technology has significant potential in the management of patients with metastatic Non-Small Cell Lung Cancer. I am thrilled for Ohio State to participate in this study aimed at evaluating clinical utility prospectively,” stated Dwight Owen, MD, MSc, thoracic medical oncologist at The James Comprehensive Cancer Center at The Ohio State University.
Echoing this sentiment, Petr Jordan, Chief Technical Officer of Onc.AI, expressed gratitude for the NCI's recognition: “We are excited about the progress we have made so far, and this grant enables us to refine our technology further” He added that this financial boost could facilitate the exploration of additional applications for their foundational deep learning radiomics biomarker technology.
About Onc.AI
Onc.AI is a forward-thinking, privately held digital health company striving to revolutionize oncology through its precision clinical management platform. Founded with the mission to advance predictive modeling for patient responses to PD-(L)1 immunotherapy, Onc.AI aims to develop a first-in-class radiomic solution that reduces unpredictability in treatment responses and enhances patient outcomes while optimizing costs for healthcare systems.
Frequently Asked Questions
What is the purpose of the $2 million grant awarded to Onc.AI?
The grant will support the further development and clinical validation of Onc.AI’s AI-based clinical decision support system for treating metastatic NSCLC.
What technology does Onc.AI utilize for cancer treatment?
Onc.AI uses deep learning to analyze imaging data, allowing for improved predictions regarding patient responses to treatment.
How does the grant impact Onc.AI's research initiatives?
The funding will enable Onc.AI to conduct a multi-institutional clinical study and further validate their AI technologies in real-world clinical settings.
What is the significance of the ASCO meeting for Onc.AI?
The ASCO meeting was significant for Onc.AI as they presented successful outcomes demonstrating their innovative clinical decision support capabilities.
Who are the key experts involved in the Onc.AI study?
Experts like Dwight Owen, MD, MSc, from The James Comprehensive Cancer Center are participating in evaluating the clinical utility of Onc.AI's technology.